RxDoctor Payments Data

William Richheimer, MD

Ophthalmology · Sheridan, CONPI 1376583575

Payments from drug & device makers

$3,283in general payments, 2019–2025

Across 127 payments — averaging $25.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$454
  • Rxsight Inc$356
  • Glaukos Corporation$298
  • Ocular Therapeutix, Inc.$183
  • Staar Surgical Company$171
  • plus $709 from 15 others

What the payments were for

  • Speaking & faculty fees$281%
  • Food & beverage$3,16796%
  • Entertainment$883%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,283 in reported general payments places this provider in the 70th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$712,740
Medicare patients
909
Services billed
2,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketorolac Tromethamine1,102$27,492
RestasisCyclosporine16$19,528
Prednisolone Acetate234$9,718
Fluorometholone30$2,904
MoxifloxacinMoxifloxacin Hcl59$1,823
ValacyclovirValacyclovir Hcl20$1,345
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$451
ErythromycinErythromycin Base36$445
Latanoprost49$416
Ofloxacin35$326
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$454$19,52816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 262 ophthalmology providers in Colorado.

Other ophthalmology in Sheridan

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →